Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China

Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special ...
Badgers Wire

Michigan man gets new Roctavian gene therapy for hemophilia A

Henry Ford Health has treated the first Michigan patient outside clinical trials with Roctavian, the newly approved gene ...
Monthly Prescribing Reference

Alhemo Approved for Treatment of Hemophilia A or B With Inhibitors

Findings showed concizumab-treated patients had an 86% reduction in annualized bleeding rate compared with no prophylaxis. The Food and Drug Administration (FDA) has approved Alhemo ® (concizumab-mtci ...
Medscape

FDA Approves Pfizer's Hympavzi for Hemophilia A, B

The US Food and Drug Administration (FDA) has approved Hympavzi (marstacimab, Pfizer) as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years or older who ...
WebMD

Alhemo: A New Daily Injection to Help Prevent Bleeding in Hemophilia A and B

What Is Alhemo, and Why Does It Matter? Alhemo (concizumab-mtci) is a medicine approved to help prevent bleeding in people aged 12 or older with hemophilia A or B who don’t have inhibitors to certain ...
MarketWatch

Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for the ...
MedPage Today

Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors

The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents ages 12 years and older with hemophilia A without factor VIII ...
Healio

FDA approves Hympavzi for hemophilia A or B without inhibitors

Please provide your email address to receive an email when new articles are posted on . The FDA approved marstacimab-hncq for treatment of certain individuals with hemophilia. The indication applies ...
Vietnam Investment Review on MSN

Belief BioMed gains Macao approval for hemophilia B gene therapy

SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical ...
MedPage Today

Concizumab Prophylaxis Reduced Bleeding Rates in Hemophilia

Compared with on-demand treatment, prophylaxis with concizumab -- designed to achieve hemostasis in all hemophilia types -- reduced annualized bleeding rates among patients who have hemophilia A or B ...
FiercePharma

Sanofi dives deep into the lives of hemophilia patients, partnering with pollster to learn their needs

Sanofi has taken a deep dive into the lives of hemophilia patients, caregivers and providers. Working with The Harris Poll, the French drugmaker surveyed 2,700 people in 11 countries to understand how ...
WebMD

Managing Hemophilia With Alhemo

Hemophilia is a rare genetic condition that keeps your blood from clotting, leading to bleeding problems. Bleeding can happen at any time (spontaneous) or as a result of trauma (injury, cut, or fall).